🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 16 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
20/12/2023 18,21 18,30 17,00 17,09 -6,82% 7,14% 735.300
19/12/2023 17,90 18,40 17,78 18,34 +3,50% 3,46% 795.100
18/12/2023 18,02 18,02 17,44 17,72 -2,21% 3,22% 950.900
15/12/2023 17,71 18,41 17,50 18,12 +2,78% 5,17% 2.953.400
14/12/2023 17,73 17,81 17,12 17,63 +2,26% 3,89% 1.866.800
13/12/2023 16,07 17,34 16,07 17,24 +6,68% 7,90% 871.000
12/12/2023 16,03 16,33 15,71 16,16 +1,00% 3,87% 623.400
11/12/2023 15,62 16,04 15,19 16,00 +1,46% 5,47% 539.200
08/12/2023 15,66 16,02 15,40 15,77 +0,83% 3,96% 497.000
07/12/2023 15,89 16,06 15,51 15,64 -1,08% 3,46% 604.600
06/12/2023 15,81 16,31 15,62 15,81 +0,89% 4,40% 568.100
05/12/2023 15,91 16,11 15,59 15,67 -2,67% 3,27% 571.700
04/12/2023 16,04 16,57 15,94 16,10 +0,19% 3,93% 991.000
01/12/2023 14,95 16,10 14,38 16,07 +6,71% 11,51% 801.300
30/11/2023 15,03 15,36 14,90 15,06 +3,01% 3,06% 864.800
29/11/2023 14,24 14,99 14,24 14,62 +3,32% 5,23% 543.400
28/11/2023 14,08 14,18 13,67 14,15 +0,64% 3,62% 338.700
27/11/2023 14,12 14,12 13,50 14,06 +0,00% 4,43% 900.900
24/11/2023 13,82 14,16 13,82 14,06 +1,37% 2,49% 163.300
22/11/2023 14,07 14,20 13,62 13,87 +0,43% 4,12% 443.100
21/11/2023 13,77 14,10 13,53 13,81 -1,07% 4,18% 466.100
20/11/2023 14,61 14,88 13,89 13,96 -3,66% 6,74% 571.300
17/11/2023 14,19 14,81 14,19 14,49 +3,13% 4,37% 540.600
16/11/2023 14,52 14,57 13,83 14,05 -3,44% 5,10% 527.600
15/11/2023 14,23 15,25 14,23 14,55 +1,11% 7,17% 682.600
14/11/2023 13,89 14,55 13,89 14,39 +7,15% 4,75% 914.400
13/11/2023 13,38 13,58 12,95 13,43 -0,81% 4,71% 484.000
10/11/2023 13,65 13,75 13,11 13,54 -1,46% 4,73% 842.200
09/11/2023 16,10 16,10 13,72 13,74 -14,18% 14,78% 834.800
08/11/2023 16,54 16,95 15,59 16,01 -2,67% 8,22% 1.030.600